TransEnterix Announces Appointment of Shameze Rampertab as Chief Financial Officer
August 13 2020 - 6:55AM
Business Wire
TransEnterix, Inc. (NYSE American: TRXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to improve minimally invasive surgery, today announced
that Shameze Rampertab has been appointed as the Company’s
Executive Vice President and Chief Financial Officer, effective
August 24, 2020.
“We are delighted to welcome Shameze to our team during this
important time in TransEnterix’s journey,” said Anthony Fernando,
TransEnterix President and Chief Executive Officer. “His extensive
experience at implementing financial strategies and sourcing equity
and debt financing options will be invaluable as we continue
towards our goals for 2020 and beyond. I am confident Shameze will
make an immediate positive impact on the organization and help lead
TransEnterix through its next phase of growth.”
Mr. Rampertab brings over 20 years of financial leadership
experience in the healthcare sector to the Company. In addition to
significant experience in corporate leadership roles, his
background also includes time spent as an investment banker and
sell-side equity research analyst. Most recently, Mr. Rampertab
served as interim Chief Executive Officer (December 2019 to June
2020), Chief Financial Officer (March 2016 to August 2020), and
Corporate Secretary and a director (April 2016 to August 2020) at
Zomedica Pharmaceuticals Corp., an animal health company. Before
joining Zomedica, he served as CFO and Secretary (October 2014 to
November 2015) at Profound Medical Corp., a thermal ablation
medical device company. Prior to that, he was CFO and Vice
President of Finance (October 2010 to October 2014) for
Intellipharmaceutics International Inc., a NASDAQ and TSX listed
specialty pharmaceutical company. He received his Chartered
Professional Accountant (CPA) and Chartered Accountant (CA)
designations from the Chartered Professional Accountants of Canada,
and earned his MBA from McMaster University and Bachelor of Science
in molecular genetics and molecular biology from the University of
Toronto.
Mr. Rampertab added, “I am thrilled to join TransEnterix, a
company I have long admired for its innovative robotic solutions to
enable digital laparoscopy. I look forward to working with Anthony
and the entire team to deliver commercial adoption and drive
long-term growth.”
About TransEnterix
At TransEnterix, Inc., we are digitizing the interface between
the surgeon and the patient to improve minimally invasive surgery
(MIS) through a new category of care called Digital Laparoscopy.
Digitizing the interface enables the use of advanced capabilities
like augmented intelligence, connectivity and robotics in
laparoscopy, and allows us to address the current clinical,
cognitive and economic shortcomings in surgery. The system features
the first machine vision system for use in robotic surgery which is
powered by the new intelligent Surgical Unit (ISU) that enables
augmented intelligence in surgery. The Senhance® Surgical System
brings the benefits of Digital Laparoscopy to patients around the
world while staying true to the principles of value-based
healthcare. Learn more about Digital Laparoscopy with the Senhance
Surgical System here: https://Senhance.com/. Now available for sale
in the US, the EU, Japan, and select other countries. For a
complete list of indications for use, please visit
https://www.transenterix.com/indications-for-use/.
Forward-Looking Statements
This press release includes statements regarding the appointment
of Shameze Rampertag as the Company’s Executive Vice President and
Chief Financial Officer. These statements and other statements
regarding our future plans and goals constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control and which
may cause results to differ materially from expectations and
include whether Mr. Rampertag’s extensive experience will be
invaluable as TransEnterix continues towards its 2020 goals and
beyond; whether Mr. Rampertag can help lead TransEnterix through
its next phase of growth and whether Mr. Rampertag, working with
Anthony Fernando and the entire TransEnterix team, can deliver
commercial adoption and drive long-term growth. For a discussion of
the risks and uncertainties associated with TransEnterix and its
business, please review our filings with the Securities and
Exchange Commission (SEC), including our Annual Report on Form 10-K
for the year ended December 31, 2019, filed with the SEC on March
16, 2020 and our other filings we make with the SEC. You are
cautioned not to place undue reliance on these forward-looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the origination date of
this press release. We undertake no obligation to publicly update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200813005262/en/
Investor Contact: Mark Klausner, +1 443-213-0501
invest@transenterix.com or Media Contact: Terri Clevenger, +1
203-682-8297 terri.clevenger@icrinc.com
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Apr 2023 to Apr 2024